Online inquiry

IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1468MR)

This product GTTS-WQ1468MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1468MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10857MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ10322MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ8611MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ5496MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ2782MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ11058MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ12866MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ1035MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW